[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

LUC00219I2 - - Google Patents

Download PDF

Info

Publication number
LUC00219I2
LUC00219I2 LU00219C LUC00219C LUC00219I2 LU C00219 I2 LUC00219 I2 LU C00219I2 LU 00219 C LU00219 C LU 00219C LU C00219 C LUC00219 C LU C00219C LU C00219 I2 LUC00219 I2 LU C00219I2
Authority
LU
Luxembourg
Application number
LU00219C
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of LUC00219I2 publication Critical patent/LUC00219I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU00219C 2011-07-29 2021-08-18 LUC00219I2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161513428P 2011-07-29 2011-07-29
US201161513432P 2011-07-29 2011-07-29
US201261610178P 2012-03-13 2012-03-13
US201261653588P 2012-05-31 2012-05-31
US201261654651P 2012-06-01 2012-06-01
PCT/US2012/048319 WO2013019548A1 (fr) 2011-07-29 2012-07-26 Modulateurs de transport nucléaire contenant de l'hydrazide et leurs utilisations

Publications (1)

Publication Number Publication Date
LUC00219I2 true LUC00219I2 (fr) 2022-10-07

Family

ID=46634546

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00219C LUC00219I2 (fr) 2011-07-29 2021-08-18

Country Status (35)

Country Link
US (9) US9079865B2 (fr)
EP (3) EP3333164B1 (fr)
JP (3) JP6005740B2 (fr)
KR (6) KR20200088518A (fr)
CN (5) CN117229268A (fr)
AR (1) AR087342A1 (fr)
AU (6) AU2012290454B2 (fr)
BR (1) BR112014001934B1 (fr)
CA (1) CA2842362C (fr)
CL (2) CL2014000225A1 (fr)
CO (1) CO6960539A2 (fr)
CY (2) CY1119783T1 (fr)
DK (2) DK2736887T3 (fr)
EA (1) EA201490407A1 (fr)
ES (2) ES2655645T3 (fr)
FR (1) FR21C1042I2 (fr)
GE (1) GEP201706616B (fr)
HK (2) HK1198477A1 (fr)
HR (1) HRP20180014T1 (fr)
HU (2) HUE036058T2 (fr)
LT (2) LT2736887T (fr)
LU (1) LUC00219I2 (fr)
ME (1) ME02936B (fr)
MX (1) MX349712B (fr)
NL (1) NL301119I2 (fr)
NO (1) NO2021033I1 (fr)
PE (1) PE20141170A1 (fr)
PL (2) PL3333164T3 (fr)
PT (1) PT2736887T (fr)
RS (1) RS56823B1 (fr)
SI (1) SI2736887T1 (fr)
TW (1) TWI574957B (fr)
UA (1) UA115532C2 (fr)
WO (1) WO2013019548A1 (fr)
ZA (1) ZA201401223B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5816635B2 (ja) 2010-03-05 2015-11-18 カリオファーム セラピューティクス，インコーポレイテッド 核輸送調節剤およびその使用
EP2665362B1 (fr) 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Modulateurs du transport nucléaire contenant des oléfines et leurs utilisations
MX350442B (es) * 2011-07-29 2017-09-06 Karyopharm Therapeutics Inc Moduladores del transporte nuclear y usos de los mismos.
TWI574957B (zh) * 2011-07-29 2017-03-21 佳佑製藥治療公司 含有醯肼的核運輸調控子及其用途
EP2805713B1 (fr) 2012-01-18 2018-10-10 Bioneer Corporation Complexe nanoparticule magnétique-samirna et son procédé de préparation
MX364992B (es) * 2012-05-09 2019-05-17 Biogen Ma Inc Moduladores del transporte nuclear y usos de los mismos.
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
EP2970196B1 (fr) 2013-03-15 2020-11-25 Global Blood Therapeutics, Inc. Composés et leurs utilisations pour la modulation de l'hémoglobine
EP2968278B8 (fr) * 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Procédés de promotion de la cicatrisation d'une plaie à l'aide d'inhibiteurs de crm1
EA029743B1 (ru) * 2013-06-21 2018-05-31 Кариофарм Терапевтикс, Инк. Модуляторы ядерного транспорта и их применение
WO2014205393A1 (fr) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Modulateurs de transport nucléaire et leurs utilisations
PL3018208T3 (pl) 2013-07-05 2020-09-21 Bioneer Corporation Ulepszona struktura oligonukleotydowa typu nanocząstki o wysokiej wydajności i sposób jej wytwarzania
MX2016000021A (es) 2013-07-05 2017-04-06 Bioneer Corp Sirna virus especifico del dengue, estructura arn oligo helicoidal, y composicion para la supresion de proliferacion del virus del dengue que comprende la estructura arn.
KR20150006743A (ko) * 2013-07-09 2015-01-19 (주)바이오니아 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
EP3074007B1 (fr) * 2013-11-28 2019-07-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé et compositions pharmaceutiques de traitement de béta-thalassémies
KR102208588B1 (ko) 2014-04-04 2021-01-28 (주)바이오니아 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물
JP6777626B2 (ja) 2014-08-15 2020-10-28 カリオファーム セラピューティクス，インコーポレイテッド セリネクソールの多形体
WO2017117535A1 (fr) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Modulateurs de transport nucléaire et leurs utilisations
EP3397633A1 (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire et leurs utilisations
US11034675B2 (en) 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
EP3241830A1 (fr) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Derivés de bicycles condensés hétérocycliques utilisés comme pesticides
EP3512515A1 (fr) 2016-09-16 2019-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de la mastocytose systémique
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
WO2018129227A1 (fr) 2017-01-05 2018-07-12 Watson Laboratories Inc. Nouvelles formes cristallines de sélinexor et leur procédé de préparation
CN106831617A (zh) * 2017-01-17 2017-06-13 广州市闻皓生物科技有限公司 一种Selinexor中间体的合成工艺
CN106831731B (zh) * 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
WO2018191707A2 (fr) * 2017-04-13 2018-10-18 Brown University Régulateur nucléocytoplasmique de facteurs de transcription associés à l'autophagie
WO2019232724A1 (fr) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Composés en tant que modulateurs de transport nucléaire et leurs utilisations
CN108947982A (zh) * 2018-08-16 2018-12-07 刘璐 治疗非酒精性脂肪肝病的吡嗪衍生物、组合物和应用
WO2020092965A1 (fr) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 en tant que biomarqueur pour des traitements utilisant des inhibiteurs de xpo1
CN111606890A (zh) 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
CN113423468A (zh) 2019-03-20 2021-09-21 庄信万丰股份有限公司 塞利尼索的共晶体形式
CA3135712A1 (fr) 2019-05-01 2020-11-05 Brian Clinton AUSTAD Procede de preparation d'inhibiteurs de xpo1 et intermediaires destines a etre utilises dans la preparation d'inhibiteurs de xpo1
EP3808742A1 (fr) 2019-10-16 2021-04-21 Sandoz AG Polymorphe de selinexor
WO2021163338A1 (fr) 2020-02-11 2021-08-19 Karyopharm Therapeutics Inc. Inhibiteurs de xpo1 destinés à être utilisés dans le traitement du cancer
WO2021195360A1 (fr) 2020-03-27 2021-09-30 Landos Biopharma, Inc. Ligands de plxdc2
WO2021202745A1 (fr) 2020-03-31 2021-10-07 Karyopharm Therapeutics Inc. Traitement du covid-19 à l'aide d'un composé sine
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2021252874A1 (fr) 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Inhibiteurs de xpo1 destinés à être utilisés dans le traitement du cancer
WO2021252905A1 (fr) 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Biomarqueurs pour la réponse à des inhibiteurs de l'exportine 1 chez des patients atteints d'un lymphome diffus à grandes cellules b
WO2021252900A1 (fr) 2020-06-11 2021-12-16 Karyopharm Therapeutics Inc. Biomarqueurs pour la réponse à des inhibiteurs de l'exportine 1 chez des patients atteints d'un myélome multiple
WO2022087218A1 (fr) 2020-10-21 2022-04-28 Karyopharm Therapeutics Inc. Forme cristalline de sélinexor
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
WO2022143779A1 (fr) * 2020-12-29 2022-07-07 南京明德新药研发有限公司 Composé contenant un alcényle et son application
WO2022232417A1 (fr) 2021-04-28 2022-11-03 Karyopharm Therapeutics Inc. Biomarqueurs pour la réponse à des inhibiteurs de l'exportine 1 chez des patients atteints d'un myélome multiple
WO2022246065A1 (fr) 2021-05-19 2022-11-24 Karyopharm Therapeutics Inc. Biomarqueur calb1 utilisé dans le traitement de liposarcome dé-différencié à l'aide d'inhibiteurs de xpo1, tels que le sélinexor
CN116514773A (zh) * 2023-04-24 2023-08-01 重庆汉佩生物科技有限公司 一种Verdinexor(KPT-335)及其盐酸盐的合成方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
JPS5661360A (en) * 1979-10-25 1981-05-26 Teijin Ltd 1-substituted imidazole derivative and its preparation
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en) * 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
WO1996016040A1 (fr) 1994-11-23 1996-05-30 Neurogen Corporation Certains derives 4-aminomethyl 2-substitues de l'imidazole et derives 2-aminomethyl 4-substitues de l'imidazole, nouvelles categories de ligands specifiques du sous-type du recepteur de la dopamine
US20030018025A1 (en) * 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
WO1997015567A1 (fr) 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh Heterocycles a 5 chainons, medicaments contenant ces composes, utilisation et procede de production correspondants
ES2273364T3 (es) 1996-04-04 2007-05-01 SHIONOGI & CO., LTD. Compuestos dde d[cefemo y composiciones farmaceuticas que contienen estos compuestos.
EP0913392B1 (fr) 1996-04-25 2003-07-02 Nissan Chemical Industries, Limited Derives ethyleniques et agents pesticides
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
AU2960599A (en) 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
ES2257441T3 (es) 2000-09-29 2006-08-01 Topotarget Uk Limited Compuestos de acido carbonico que comprenden un enlace amino como inhibidores hdac.
AU2002327627B2 (en) 2001-09-14 2006-09-14 Methylgene Inc. Inhibitors of histone deacetylase
WO2004037248A2 (fr) 2002-10-24 2004-05-06 Carex Sa Modulation de l'activite des recepteurs actives par les proliferateurs de peroxysomes
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
MXPA05004505A (es) * 2002-11-01 2005-07-26 Takeda Pharmaceutical Agente para prevenir o tratar la neuropatia.
US7342115B2 (en) 2002-11-08 2008-03-11 Neurogen Corporation 3-substituted-6-aryl pyridines
EP1599447A1 (fr) 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands modulant des recepteurs du type lxr
EP2261218B1 (fr) 2004-05-26 2013-04-03 Eisai R&D Management Co., Ltd. Imidazolverbindung zur Verwendung als Intermediat in der Herstellung von Cinnamid-Verbindungen
CA2575039A1 (fr) 2004-08-11 2006-02-16 Kyorin Pharmaceutical Co., Ltd. Derive d'acide aminio beneoique formant un cycle atrypique
WO2006019020A1 (fr) 2004-08-16 2006-02-23 Sankyo Company, Limited Urées de substitution
EP1849465A4 (fr) 2005-02-18 2008-12-24 Takeda Pharmaceutical Agent de controle de la fonction du recepteur gpr34
KR101439557B1 (ko) 2005-11-15 2014-09-11 오츠카 세이야쿠 가부시키가이샤 옥사졸 화합물 및 제약 조성물
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
EP1992618B1 (fr) 2006-03-09 2012-01-18 Eisai R&D Management Co., Ltd. Dérivé polycyclique de cinnamide
WO2007118137A1 (fr) 2006-04-07 2007-10-18 Methylgene Inc. Dérivés de benzamide utilisés en tant qu'inhibiteurs de l'histone désacétylase
KR101507173B1 (ko) 2006-04-18 2015-03-30 닛뽕 케미파 가부시키가이샤 페록시좀 증식제 활성화 수용체 δ 의 활성화제
DE102006024024A1 (de) * 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
JP4999923B2 (ja) 2006-06-13 2012-08-15 中国科学院上海薬物研究所 複素環非ヌクレオシド系化合物、抗ウィルス医薬組成物、及びウィルス性疾病治療薬物
CN100503571C (zh) 2006-07-12 2009-06-24 中国药科大学 四氢异喹啉类衍生物、其制备方法及其医药用途
CA2658925C (fr) 2006-07-27 2015-07-14 Amorepacific Corporation Nouveaux derives de sulfonylamino acrylamide, isomeres de ceux-ci, ou sels acceptables sur le plan pharmaceutique de ceux-ci utilises en tant qu'antagonistes du recepteur vanilloide, et compositions pharmaceutiquesles contenant
AU2007292155B2 (en) 2006-09-05 2012-11-01 Kyowa Kirin Co., Ltd. Imidazole derivative
EP1942104A1 (fr) 2006-12-20 2008-07-09 sanofi-aventis Hétéroarylcyclopropanecarboxamide et leur utilisation pharmaceutique
EP1939180A1 (fr) 2006-12-20 2008-07-02 sanofi-aventis Hétéroarylacrylamides et leur utilisation en tant que médicament pour la stimulation de l'expression de la synthase NO endotheliale
EP2124927A2 (fr) * 2007-02-26 2009-12-02 Kosan Biosciences Incorporated Composés de carbamate
EP2003118A1 (fr) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Dérivés d'acides de cannelle en tant que modulateurs du récepteur EP2
US8106083B2 (en) 2008-08-08 2012-01-31 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
CA2767661A1 (fr) 2009-07-09 2011-01-13 Crescendo Therapeutics, Llc Procede de guerison de lesion et de modulation de cicatrice
US8518968B2 (en) 2009-12-04 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
JP5816635B2 (ja) * 2010-03-05 2015-11-18 カリオファーム セラピューティクス，インコーポレイテッド 核輸送調節剤およびその使用
EP2665362B1 (fr) 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Modulateurs du transport nucléaire contenant des oléfines et leurs utilisations
MX350442B (es) 2011-07-29 2017-09-06 Karyopharm Therapeutics Inc Moduladores del transporte nuclear y usos de los mismos.
TWI574957B (zh) * 2011-07-29 2017-03-21 佳佑製藥治療公司 含有醯肼的核運輸調控子及其用途
WO2013020024A2 (fr) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Composés de maléimide et méthodes de traitement
MX364992B (es) 2012-05-09 2019-05-17 Biogen Ma Inc Moduladores del transporte nuclear y usos de los mismos.
EP2968278B8 (fr) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Procédés de promotion de la cicatrisation d'une plaie à l'aide d'inhibiteurs de crm1
WO2014152263A1 (fr) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Modulateurs de transport nucléaire contenant une exo-oléfine et leurs utilisations
EA029743B1 (ru) 2013-06-21 2018-05-31 Кариофарм Терапевтикс, Инк. Модуляторы ядерного транспорта и их применение
WO2014205393A1 (fr) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Modulateurs de transport nucléaire et leurs utilisations
US11567063B2 (en) 2013-11-15 2023-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for assessing cell viability or predicting cell response to a treatment using cell movement
JP6631616B2 (ja) 2014-07-26 2020-01-15 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用
JP6777626B2 (ja) 2014-08-15 2020-10-28 カリオファーム セラピューティクス，インコーポレイテッド セリネクソールの多形体
EP3397633A1 (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire et leurs utilisations
WO2017117535A1 (fr) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Modulateurs de transport nucléaire et leurs utilisations
US11034675B2 (en) 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
JP6765198B2 (ja) 2016-03-10 2020-10-07 パナソニック株式会社 潜熱蓄熱材及びそれを用いる蓄熱システム
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
WO2018129227A1 (fr) 2017-01-05 2018-07-12 Watson Laboratories Inc. Nouvelles formes cristallines de sélinexor et leur procédé de préparation

Also Published As

Publication number Publication date
CN110372672B (zh) 2023-09-29
CO6960539A2 (es) 2014-05-30
HUE036058T2 (hu) 2018-06-28
JP2014521652A (ja) 2014-08-28
TW201311666A (zh) 2013-03-16
HRP20180014T1 (hr) 2018-04-20
CL2015001257A1 (es) 2015-09-21
BR112014001934A2 (pt) 2017-02-21
AU2020203121A1 (en) 2020-05-28
CY2021028I1 (el) 2022-03-24
RS56823B1 (sr) 2018-04-30
AU2020203121B2 (en) 2022-02-17
EP2736887A1 (fr) 2014-06-04
KR20240060688A (ko) 2024-05-08
EP2736887B1 (fr) 2017-10-18
FR21C1042I2 (fr) 2022-09-02
HUS2100030I1 (hu) 2021-09-28
WO2013019548A1 (fr) 2013-02-07
CN103874690B (zh) 2016-07-06
CN106083827B (zh) 2019-09-17
US20200339521A1 (en) 2020-10-29
AU2016210682B2 (en) 2018-04-19
US10544108B2 (en) 2020-01-28
US10173987B2 (en) 2019-01-08
UA115532C2 (uk) 2017-11-27
US20140364408A1 (en) 2014-12-11
CN110372673B (zh) 2023-10-03
CN106083827A (zh) 2016-11-09
LTPA2021007I1 (fr) 2021-08-25
US11034660B2 (en) 2021-06-15
AR087342A1 (es) 2014-03-19
JP6309057B2 (ja) 2018-04-11
AU2012290454B2 (en) 2016-05-05
AU2022203265A1 (en) 2022-06-02
NL301119I2 (nl) 2021-09-15
CY1119783T1 (el) 2018-06-27
US8999996B2 (en) 2015-04-07
US20140235653A1 (en) 2014-08-21
KR20200088518A (ko) 2020-07-22
ZA201401223B (en) 2022-03-30
US20190330164A1 (en) 2019-10-31
US9079865B2 (en) 2015-07-14
DK3333164T3 (da) 2023-09-18
US11787771B2 (en) 2023-10-17
AU2018202441A1 (en) 2018-04-26
JP6675431B2 (ja) 2020-04-01
CL2014000225A1 (es) 2014-12-05
KR20230042129A (ko) 2023-03-27
NZ621904A (en) 2016-05-27
TWI574957B (zh) 2017-03-21
CN103874690A (zh) 2014-06-18
CA2842362C (fr) 2020-06-16
US9714226B2 (en) 2017-07-25
US20240279188A1 (en) 2024-08-22
EP4234545A3 (fr) 2023-09-06
FR21C1042I1 (fr) 2021-11-19
HK1198477A1 (en) 2015-05-08
JP2018111713A (ja) 2018-07-19
US20160304472A1 (en) 2016-10-20
AU2024202868A1 (en) 2024-05-23
US20220073478A1 (en) 2022-03-10
EP3333164A1 (fr) 2018-06-13
MX349712B (es) 2017-08-09
EP4234545A2 (fr) 2023-08-30
JP2017036287A (ja) 2017-02-16
CN110372673A (zh) 2019-10-25
PT2736887T (pt) 2018-01-15
PL3333164T3 (pl) 2023-12-18
NO2021033I1 (no) 2021-09-06
LT2736887T (lt) 2018-02-12
KR20190045399A (ko) 2019-05-02
ES2954991T3 (es) 2023-11-28
KR20210083380A (ko) 2021-07-06
EP3333164B1 (fr) 2023-06-07
AU2012290454A1 (en) 2014-03-20
US20150274698A1 (en) 2015-10-01
AU2018202441B2 (en) 2020-02-13
JP6005740B2 (ja) 2016-10-12
NZ719623A (en) 2017-12-22
HK1256745A1 (zh) 2019-10-04
ME02936B (fr) 2018-04-20
GEP201706616B (en) 2017-02-10
NL301119I1 (fr) 2021-08-04
CY2021028I2 (el) 2022-03-24
ES2655645T3 (es) 2018-02-21
CA2842362A1 (fr) 2013-02-07
KR102022716B1 (ko) 2019-09-18
AU2016210682A1 (en) 2016-08-18
CN117229268A (zh) 2023-12-15
LTC2736887I2 (fr) 2022-10-25
KR102136768B1 (ko) 2020-07-23
MX2014001181A (es) 2014-07-14
US9206158B2 (en) 2015-12-08
DK2736887T3 (en) 2018-01-02
KR20140066179A (ko) 2014-05-30
PL2736887T3 (pl) 2018-03-30
BR112014001934B1 (pt) 2020-12-15
CN110372672A (zh) 2019-10-25
US20180127384A1 (en) 2018-05-10
EA201490407A1 (ru) 2014-05-30
SI2736887T1 (en) 2018-04-30
PE20141170A1 (es) 2014-09-16

Similar Documents

Publication Publication Date Title
BR112014014565A2 (fr)
BR112013022641A2 (fr)
BR112013031251A2 (fr)
BR112013027245A2 (fr)
AP3853A (fr)
BR112013024383A2 (fr)
BR112013023185A2 (fr)
BR112013022995A2 (fr)
BR112013026905A2 (fr)
BR112013017670A2 (fr)
BR112013027830A2 (fr)
BR112013023927A2 (fr)
BR112013026744A2 (fr)
BR112013024365A2 (fr)
BR112013028733A2 (fr)
BR112013027121A2 (fr)
BR112013027452A2 (fr)
AP2016009466A0 (fr)
BR112013031556A2 (fr)
BR112013026790A2 (fr)
BR112013024588A2 (fr)
BR112013032380A2 (fr)
BR112013032377A2 (fr)
BR112013032368A2 (fr)
BR112013026895A2 (fr)